Sandra Strauss is part of the oncology team on the Sarcoma Unit at University College Hospital, and specialises in the systemic treatment of bone and soft tissue sarcomas in both adults and teenagers. She completed a Cancer Research UK Clinical Fellowship to obtain a PhD (University of London) at St Bartholomew's Hospital investigating pre-clinical and clinical effects of novel treatments for cancer, and investigating translational markers to improve their effects.
Rothermundt C, Whelan JS, Dileo P, Strauss SJ, Coleman J, Briggs TW, Haile SR, Seddon BM. What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients. Br J Cancer. 2014 May 13;110(10):2420-6. doi: 10.1038/bjc.2014.200. Epub 2014 Apr 15
Fernanda Amary M, Ye H, Berisha F, Khatri B, Forbes G, Lehovsky K, Frezza AM, Behjati S, Tarpey P, Pillay N, Campbell PJ, Tirabosco R, Presneau N, Strauss SJ, Flanagan AM. Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy. Cancer Med. 2014 Aug;3(4):980-7. doi: 10.1002/cam4.268. Epub 2014 May 27.
Anninga J, Cleton-Jansen AM, Hassan B, Amary MF, Baumhoer D , Blay JY, Brugieres L , Ferrari S, Jürgens H, Kempf-Bielack B , Kovar H, Myklebost O, Nathrath M, Picci P , Riegman R, Schilham MW , Soliman R, Stark D, Strauss S, Sydes M, Tarpey P, Thomas D, Whelan J, Wilhelm M, Zamzam M, Gelderblom H, Bielack SSWorkshop report on the 2nd Joint ENCCA/ EuroSARC European bone sarcoma network meeting: integration of clinical trials with tumour biology. Clin Sarcoma Research, 2014, 4:4
Ban J, Fourtouna A, Aryee D, van der Ent W, Kauer M, Niedan S, Machado I, Rodriguez-Galindo C, Tirado OM, Alberghini M, Flanagan AM, Berg V, Strauss SJ, Scotlandi K, Lawlor ER, Snaar-Jagalska E, Llombart-Bosch A, Kovar H. Suppression of deacetylase SIRT1 links HEY1 to p53 activation in tumor suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma. Cancer Research 2014;74(22):6578-88.
Whelan JS, McTiernan A, Cooper N, Wong Y, Francis M, Vernon S, Strauss S. Incidence and survival of malignant bone sarcomas in England 1979-2007. Int Journal of Cancer, DOI: 10.1002/ijc.26426
Strauss SJ, Ng T, Mendoza-Naranjo A, Whelan J, Sorensen P Understanding micrometastatic disease and “anoikis” resistance in Ewing’s family Tumours (EFT) and osteosarcoma.. The Oncologist 2010;15:627-35
Windsor RE, Strauss SJ, Kallis C, Wood N, Whelan JS.Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer, 2011 DOI: 10.1002/cncr.26472
Windsor R, Strauss SJ, Seddon B, et al. Experimental Therapies in Ewing's Sarcoma. Expert Opinion On Investigational Drugs (in press).
Mendoza-Naranjo A, El-Naggar A, Wai DH, Mistry P, Lazic N, Ayala FR, da Cunha IW, Rodriguez-Viciana P, Cheng H, Tavares Guerreiro Fregnani JH, Reynolds P, Arceci RJ, Nicholson A, Triche TJ, Soares FA, Flanagan AM, Wang YZ, Strauss SJ, Sorensen PH.. ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Mol Med. 2013 May 16. doi: 10.1002/emmm.201202343. [Epub ahead of print]
Whelan J, Khan A, Sharma A, Rothermundt C, Dileo P, Michelagnoli M, Seddon B, Strauss S. Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing’s and other Small Round Cell Sarcomas Clinical Sarcoma Research 2012, 2:12 (21 September 2012)
Lombardo CM, Welsh SJ, Strauss SJ, Dale AG, Todd AK, Nanjunda R, Wilson WD, Neidle S. A novel series of G-quadruplex ligands with selectivity for HIF-expressing osteosarcoma and renal cancer cell lines. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5984-8.
Strauss SJ, McTiernan A, Whelan JS. Late Relapse in Osteosarcoma: implications for follow-up and screening. Pediatr Blood Cancer 43 (6): 692 – 697, 2004.
Strauss SJ, Marples M, Meyer T, et al. A Phase I (Tumour site specific) trial of Temozolomide and Carboplatin in patients with advanced melanoma. Br J Cancer 89 (10):1901-5, 2003.
Strauss SJ, McTiernan A, Driver D, et al. A single centre experience of a dose intensive induction regimen (VIDE) in patients with Ewing’s Family of Tumours. J Clin Oncol 21(15):2974-81, 2003.
Welsh SJ, Strauss SJ. Assessment of the patient with neutropenic sepsis. Br J Hosp Med (Lond). 2012 Jun;73(6):C89-92.
Rothermundt C, Whelan JS, Dileo P, Strauss SJ, Coleman J, Briggs TW, Haile SR, Seddon BM. What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients.. Br J Cancer. 2014 May
Frezza AM, Beale T, Bomanji J, Jay A, Kalavrezos N, Dileo P, Whelan J, Strauss SJ. F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment.Is [BMC Cancer. 2014 Jan 15;14:23.13;110(10):2420-6. doi: 10.1038/bjc.2014.200. Epub 2014 Apr 15
Fernanda Amary M, Ye H, Berisha F, Khatri B, Forbes G, Lehovsky K, Frezza AM, Behjati S, Tarpey P, Pillay N, Campbell PJ, Tirabosco R, Presneau N, Strauss SJ, Flanagan AM. Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy.. Cancer Med. 2014 May 27. doi: 10.1002/cam4.268. [Epub ahead of print].